Results 41 to 50 of about 27,341 (230)

Ezetimibe Attenuates Oxidative Stress and Neuroinflammation via the AMPK/Nrf2/TXNIP Pathway after MCAO in Rats

Oxidative Medicine and Cellular Longevity, 2020
Oxidative stress and neuroinflammation play essential roles in ischemic stroke-induced brain injury. Previous studies have reported that Ezetimibe (Eze) exerts antioxidative stress and anti-inflammatory properties in hepatocytes. In the present study, we
Jing Yu, Wen-na Wang, N. Matei, Xue Li, Jingjing Pang, Jun Mo, Shengpan Chen, Ji-Ping Tang, Min Yan, John H. Zhang   +9 more
semanticscholar   +1 more source

Simultaneous determination of ezetimibe and simvastatin in rat plasma by stable-isotope dilution LC-ESI–MS/MS and its application to a pharmacokinetic study

Journal of Pharmaceutical Analysis, 2014
A simple, sensitive and specific liquid chromatography–tandem mass spectrometry method was developed for simultaneous quantification of ezetimibe and simvastatin in rat plasma.
Sireesha R. Karanam, Prakash Katakam, Babu R. Chandu, Nagiat T. Hwisa, Shanta K. Adiki   +4 more
doaj   +1 more source

PCSK9 Inhibitor Use and Outcomes Using Concomitant Lipid-Lowering Therapies in the Veterans Health Administration

American Journal of Medicine Open, 2023
Background: Real-world data on use of PCSK9 inhibitors (PCSK9-Is), with or without statins and/or ezetimibe, and associated outcomes, can inform more effective prescribing.
Jessica Eloso, Asma Awad, Xinhua Zhao, Francesca E. Cunningham, Rongping Zhang, Diane Dong, Cathy Kelley, Peter A. Glassman, Sherrie L. Aspinall   +8 more
doaj   +1 more source

Ameliorative impact of ezetimibe on gentamicin-induced kidney damage; A histopathological perspective study [PDF]

Journal of Nephropathology, 2022
Introduction: Gentamicin, despite its beneficial effects, has significant nephrotoxic effects that are observed in 20% of the patients. Ezetimibe is recognized as an inhibitor of cholesterol absorption.
Elham Emami, Ali Hasanpour Dehkordi, Ahmadreza Maghsoudi, Hamid Nasri, Alireza Vahedi   +4 more
doaj   +1 more source

Early Ezetimibe Initiation After Myocardial Infarction Protects Against Later Cardiovascular Outcomes in the SWEDEHEART Registry.

Journal of the American College of Cardiology
BACKGROUND Combination lipid-lowering therapy (LLT) after myocardial infarction (MI) achieves lower low-density lipoprotein cholesterol (LDL-C) levels and better cardiovascular outcomes vs statin monotherapy.
M. Leosdottir, J. Schubert, J. Brandts, S. Gustafsson, T. Cars, Johan Sundström, T. Jernberg, Kausik K. Ray, Emil Hagström   +8 more
semanticscholar   +1 more source

Ezetimibe use and mortality after myocardial infarction: A nationwide cohort study

American Journal of Preventive Cardiology
Background: The inhibition of intestinal cholesterol absorption by ezetimibe improves outcomes after myocardial infarction (MI), yet real-world data on ezetimibe is scarce. We studied the usage of ezetimibe and association with outcome after MI. Methods:
Ville Kytö, Aleksi Tornio
doaj   +1 more source

Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy

European Journal of Preventive Cardiology, 2019
Aims The aim of this study was to evaluate the low-density lipoprotein cholesterol lowering efficacy and safety of a bempedoic acid 180 mg and ezetimibe 10 mg fixed-dose combination in patients with hypercholesterolemia and a high risk of cardiovascular ...
C. Ballantyne, U. Laufs, K. Ray, Lawrence A Leiter, H. Bays, A. Goldberg, E. Stroes, D. Macdougall, Xin Zhao, A. Catapano   +9 more
semanticscholar   +1 more source

A Multicenter, Randomized, Double-Blind, Active-Controlled, Factorial Design, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of Pitavastatin and Ezetimibe Versus Monotherapy of Pitavastatin in Patients With Primary Hypercholesterolemia.

Clinical Therapeutics, 2022
PURPOSE Pitavastatin is a unique lipophilic statin with moderate efficacy in lowering LDL-C levels by 30% to 50% with a tolerable safety profile. However, the efficacy of adding ezetimibe to pitavastatin in patients with dyslipidemia has not been well ...
Han Saem Jeong, S. Hong, Jin-man Cho, K. Han, D. Cha, S. Jo, H. Kang, S. Choi, C. Choi, E. J. Cho, Y. Jeong, H. Gwon, Byeong‐Keuk Kim, Sung Yun Lee, Sang-Hyun Kim, J. Ahn, Y. Hong, Woo-Shik Kim, Simon S. Woo, T. Park, K. Han   +20 more
semanticscholar   +1 more source

Adding ezetimibe to statin therapy: latest evidence and clinical implications

, 2018
Background: Statins are the hypolipemic treatment of choice for hyperlipidemia with confirmed atherosclerotic cardiovascular disease (ASCVD) protective effect, proven even in normolipemic patients.
Marija Vavlukis, Ana Vavlukis
core   +1 more source

Inhibitory effect of ezetimibe can be prevented by an administration interval of 4 h between alpha-tocopherol and ezetimibe [PDF]

, 2017
Tocopherol is used not only as an ethical drug but also as a supplement. In 2008, it was reported that alpha-tocopherol is partly transported via an intestinal cholesterol transporter, Niemann-Pick C1-Like 1 (NPC1L1).
Shunsuke Nashimoto, Takekuma, Yoh, Yoh Takekuma, Mitsuru Sugawara, Nashimoto, Shunsuke, Yuki Sato, Sato, Yuki, Sugawara, Mitsuru   +7 more
core   +1 more source